Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Daratumumab + Elranatamab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 13||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Elranatamab||PF-06863135|PF06863135|PF 06863135||CD3 Antibody 55||Elranatamab (PF-06863135) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05020236||Phase III||Elranatamab Daratumumab + Dexamethasone + Pomalidomide Daratumumab + Elranatamab||MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)||Recruiting||ESP | CAN||9|